Markets
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C.
Business Insider
My Markets Watchlist
Markets
News
Search
Business
Strategy
Economy
Finance
Retail
Advertising
Careers
Law
Media
Real Estate
Small Business
The Better Work Project
Personal Finance
Tech
Science
AI
Enterprise
Transportation
Startups
Innovation
Markets
News
Stocks
Indices
Commodities
Crypto
Currencies
ETFs
Lifestyle
Entertainment
Culture
Travel
Food
Health
Education
Parenting
Military & Defense
Politics
Reviews
Home
Kitchen
Style
Streaming
Pets
Tech
Deals
Gifts
Tickets
Video
Big Business
So Expensive
View From Above
Small Business
Authorized Account
Risky Business
Boot Camp
Still Standing
How Crime Works
Life Lessons
Level Up
Community
Games
Boxed
Pipeline
Knighthop
Tally
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
PRESS RELEASE GlobeNewswire
Sep. 8, 2026, 04:30 PM
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings.
H.C. Wainwright 28th Annual Global Investment Conference in New York Fireside Chat: Monday, Sept. 14, 2026, 3:30pm ET Webcast linked here and archived for 90 days on events page on the Imagene IR website
About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, olevaprubart, is a receptor targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis.
See more categories
Copyright © 2026 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.